Last reviewed · How we verify
TNFa Antagonist - Infliximab
TNFa Antagonist - Infliximab is a TNF-α antagonist (monoclonal antibody) Biologic drug developed by University of Calgary. It is currently FDA-approved for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | TNFa Antagonist - Infliximab |
|---|---|
| Sponsor | University of Calgary |
| Drug class | TNF-α antagonist (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
By blocking TNF-α, infliximab reduces the inflammatory cascade that drives autoimmune and inflammatory diseases. This leads to decreased immune cell activation, reduced production of other inflammatory mediators, and suppression of systemic inflammation. TNF-α is central to the pathogenesis of conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis
- Behçet's disease
Common side effects
- Infections (including serious infections and tuberculosis)
- Infusion reactions
- Headache
- Abdominal pain
- Nausea
- Increased risk of malignancy
- Demyelinating disease
Key clinical trials
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- A Study of Infliximab for Treatment Resistant Major Depression (PHASE4)
- PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease (PHASE4)
- Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.
- Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis (NA)
- Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (PHASE4)
- Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNFa Antagonist - Infliximab CI brief — competitive landscape report
- TNFa Antagonist - Infliximab updates RSS · CI watch RSS
- University of Calgary portfolio CI
Frequently asked questions about TNFa Antagonist - Infliximab
What is TNFa Antagonist - Infliximab?
How does TNFa Antagonist - Infliximab work?
What is TNFa Antagonist - Infliximab used for?
Who makes TNFa Antagonist - Infliximab?
What drug class is TNFa Antagonist - Infliximab in?
What development phase is TNFa Antagonist - Infliximab in?
What are the side effects of TNFa Antagonist - Infliximab?
What does TNFa Antagonist - Infliximab target?
Related
- Drug class: All TNF-α antagonist (monoclonal antibody) drugs
- Target: All drugs targeting TNF-α (Tumor Necrosis Factor-alpha)
- Manufacturer: University of Calgary — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Crohn's disease
- Indication: Drugs for Ulcerative colitis
- Compare: TNFa Antagonist - Infliximab vs similar drugs
- Pricing: TNFa Antagonist - Infliximab cost, discount & access